Literature DB >> 24854267

HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype.

Rukshana Shroff1, Thimoteus Speer2, Sophie Colin3, Marietta Charakida4, Stephen Zewinger2, Bart Staels3, Giulia Chinetti-Gbaguidi3, Inga Hettrich2, Lucia Rohrer5, Francis O'Neill4, Eve McLoughlin4, David Long6, Catherine M Shanahan7, Ulf Landmesser8, Danilo Fliser2, John E Deanfield4.   

Abstract

Endothelial dysfunction begins in early CKD and contributes to cardiovascular mortality. HDL is considered antiatherogenic, but may have adverse vascular effects in cardiovascular disease, diabetes, and inflammatory conditions. The effect of renal failure on HDL properties is unknown. We studied the endothelial effects of HDL isolated from 82 children with CKD stages 2-5 (HDL(CKD)), who were free of underlying inflammatory diseases, diabetes, or active infections. Compared with HDL from healthy children, HDL(CKD) strongly inhibited nitric oxide production, promoted superoxide production, and increased vascular cell adhesion molecule-1 expression in human aortic endothelial cells, and reduced cholesterol efflux from macrophages. The effects on endothelial cells correlated with CKD grade, with the most profound changes induced by HDL from patients on dialysis, and partial recovery observed with HDL isolated after kidney transplantation. Furthermore, the in vitro effects on endothelial cells associated with increased aortic pulse wave velocity, carotid intima-media thickness, and circulating markers of endothelial dysfunction in patients. Symmetric dimethylarginine levels were increased in serum and fractions of HDL from children with CKD. In a longitudinal follow-up of eight children undergoing kidney transplantation, HDL-induced production of endothelial nitric oxide, superoxide, and vascular cell adhesion molecule-1 in vitro improved significantly at 3 months after transplantation, but did not reach normal levels. These results suggest that in children with CKD without concomitant disease affecting HDL function, HDL dysfunction begins in early CKD, progressing as renal function declines, and is partially reversed after kidney transplantation.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24854267      PMCID: PMC4214534          DOI: 10.1681/ASN.2013111212

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  40 in total

Review 1.  Novel biological functions of high-density lipoprotein cholesterol.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  Circ Res       Date:  2012-09-28       Impact factor: 17.367

2.  Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.

Authors:  Christian Besler; Kathrin Heinrich; Lucia Rohrer; Carola Doerries; Meliana Riwanto; Diana M Shih; Angeliki Chroni; Keiko Yonekawa; Sokrates Stein; Nicola Schaefer; Maja Mueller; Alexander Akhmedov; Georgios Daniil; Costantina Manes; Christian Templin; Christophe Wyss; Willibald Maier; Felix C Tanner; Christian M Matter; Roberto Corti; Clement Furlong; Aldons J Lusis; Arnold von Eckardstein; Alan M Fogelman; Thomas F Lüscher; Ulf Landmesser
Journal:  J Clin Invest       Date:  2011-06-23       Impact factor: 14.808

3.  Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein.

Authors:  Michael Holzer; Klaus Zangger; Dalia El-Gamal; Veronika Binder; Sanja Curcic; Viktoria Konya; Rufina Schuligoi; Akos Heinemann; Gunther Marsche
Journal:  Antioxid Redox Signal       Date:  2012-05-08       Impact factor: 8.401

4.  Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation.

Authors:  Herwig-Ulf Meier-Kriesche; Rajendra Baliga; Bruce Kaplan
Journal:  Transplantation       Date:  2003-04-27       Impact factor: 4.939

5.  Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2.

Authors:  Thimoteus Speer; Lucia Rohrer; Przemyslaw Blyszczuk; Rukshana Shroff; Kira Kuschnerus; Nicolle Kränkel; Gabriela Kania; Stephen Zewinger; Alexander Akhmedov; Yi Shi; Tina Martin; Damir Perisa; Stephan Winnik; Maja F Müller; Urban Sester; Gabriel Wernicke; Andreas Jung; Ursula Gutteck; Urs Eriksson; Jürgen Geisel; John Deanfield; Arnold von Eckardstein; Thomas F Lüscher; Danilo Fliser; Ferdinand H Bahlmann; Ulf Landmesser
Journal:  Immunity       Date:  2013-03-07       Impact factor: 31.745

6.  Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome.

Authors:  Marietta Charakida; Christian Besler; Joana R Batuca; Shirish Sangle; Susanna Marques; Miguel Sousa; Guosu Wang; Dimitris Tousoulis; Jose Delgado Alves; Stavros P Loukogeorgakis; Charles Mackworth-Young; David D'Cruz; Thomas Luscher; Ulf Landmesser; John E Deanfield
Journal:  JAMA       Date:  2009-09-16       Impact factor: 56.272

7.  Impact of aortic stiffness on survival in end-stage renal disease.

Authors:  J Blacher; A P Guerin; B Pannier; S J Marchais; M E Safar; G M London
Journal:  Circulation       Date:  1999-05-11       Impact factor: 29.690

8.  Smoothing reference centile curves: the LMS method and penalized likelihood.

Authors:  T J Cole; P J Green
Journal:  Stat Med       Date:  1992-07       Impact factor: 2.373

9.  Long-term survival of children with end-stage renal disease.

Authors:  Stephen P McDonald; Jonathan C Craig
Journal:  N Engl J Med       Date:  2004-06-24       Impact factor: 91.245

Review 10.  Mechanistic insights into vascular calcification in CKD.

Authors:  Rukshana Shroff; David A Long; Catherine Shanahan
Journal:  J Am Soc Nephrol       Date:  2012-11-08       Impact factor: 10.121

View more
  46 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

2.  HDL: Beyond Atheroprotection.

Authors:  Valentina Kon; MacRae F Linton
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

Review 3.  Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.

Authors:  Dragana Lovre; Sulay Shah; Aanu Sihota; Vivian A Fonseca
Journal:  Endocrinol Metab Clin North Am       Date:  2017-12-18       Impact factor: 4.741

Review 4.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

5.  Kidney function is associated with an altered protein composition of high-density lipoprotein.

Authors:  Katya B Rubinow; Clark M Henderson; Cassianne Robinson-Cohen; Jonathan Himmelfarb; Ian H de Boer; Tomas Vaisar; Bryan Kestenbaum; Andrew N Hoofnagle
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

Review 6.  Crosstalk between the nervous system and the kidney.

Authors:  Shinji Tanaka; Mark D Okusa
Journal:  Kidney Int       Date:  2019-11-22       Impact factor: 10.612

7.  Dialysis Modalities and HDL Composition and Function.

Authors:  Michael Holzer; Gernot Schilcher; Sanja Curcic; Markus Trieb; Senka Ljubojevic; Tatjana Stojakovic; Hubert Scharnagl; Chantal M Kopecky; Alexander R Rosenkranz; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2015-03-05       Impact factor: 10.121

Review 8.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

Review 9.  Arterial Stiffness in the Heart Disease of CKD.

Authors:  Luca Zanoli; Paolo Lentini; Marie Briet; Pietro Castellino; Andrew A House; Gerard M London; Lorenzo Malatino; Peter A McCullough; Dimitri P Mikhailidis; Pierre Boutouyrie
Journal:  J Am Soc Nephrol       Date:  2019-04-30       Impact factor: 10.121

Review 10.  High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.

Authors:  Anand Rohatgi
Journal:  Prog Cardiovasc Dis       Date:  2015-05-09       Impact factor: 8.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.